- Home
- / UCB
UCB
Stock Price
€179.7
2024-10-29
Market Capitalization
€30.7 B
2024-08-26
Revenue
€5.6 B
FY, 2024
UCB Summary
Company Summary
- Overview
- UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. It offers brivaracetam, film-coated tablets, levetiracetam, nasal sprays, certolizumab pegol, and other products.
- Type
- Public
- Status
- Active
- Founded
- 1928
- HQ
- Brussels, BE | view all locations
- Website
- https://www.ucb.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kirsten Lund-Jurgensen, Executive Vice President of Supply & Technology Solutions
Dhavalkumar Patel, Executive Vice President & Chief Scientific Officer
Emmanuel Caeymaex, Executive Vice President of Immunology Solutions & Head of US
Operating MetricsView all
Patients Reached
3.5M
FY, 2020
Projects in Pipeline
12
71.4%
FY, 2020
Locations (Research and Development)
12
FY, 2019
LocationsView all
42 locations detected
Brussels, Bruxelles HQ
Belgium
Allée de la Recherche, 60
Morrisville, NC
United States
4000 Paramount Parkway, Suite 200
Smyrna, GA
United States
1950 Lake Park Drive
Melbourne, VIC
Australia
Level 1, 1155 Malvern Road
Vienna, Wien
Austria
Twin Tower, Wienerbergstrasse 11/12a
Braine-l'Alleud, Région Wallonne
Belgium
Avenue de l'Industrie
UCB Financials
Summary Financials
- Revenue (FY, 2024)
- €5.6B
- Gross profit (FY, 2024)
- €6.2B
- Net income (FY, 2024)
- €1.1B
- Cash (FY, 2024)
- €1.6B
- EBIT (FY, 2024)
- €1.3B
- Enterprise value
- $32.2B